Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238051 | 0.89 | L3MBTL1 (0.55) | L3MBTL1MAPTTDP1MAPK1NPSR1 | |
| SCHEMBL6202437 | 0.88 | ALDH1A1 (0.56) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6708138 | 0.83 | L3MBTL1 (0.50) | L3MBTL1MAPTTDP1MAPK1NPSR1 | |
| SCHEMBL16054847 | 0.81 | L3MBTL1 (0.61) | L3MBTL1MAPTTDP1MAPK1NPSR1 | |
| SCHEMBL1924050 | 0.80 | ALDH1A1 (0.62) | L3MBTL1MAPTTDP1MAPK1NPSR1 | |
| SCHEMBL15156640 | 0.80 | L3MBTL1 (0.57) | L3MBTL1MAPTTDP1MAPK1NPSR1 | |
| SCHEMBL7557697 | 0.79 | L3MBTL1 (0.54) | L3MBTL1MAPTTDP1MAPK1NPSR1 | |
| SCHEMBL5238095 | 0.78 | ALDH1A1 (0.57) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL5525074 | 0.78 | ALDH1A1 (0.59) | L3MBTL1MAPTTDP1MAPK1NPSR1 | |
| SCHEMBL21383091 | 0.78 | L3MBTL1 (0.63) | L3MBTL1MAPTTDP1MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | L3MBTL1 3619/4885MAPT 4481/4885TDP1 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.